CODX Co-Diagnostics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1692415 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY69.1%
TTM net income YoY-47.5%
TTM EPS YoY60.1%
Revenue 3-yr CAGR-43.1%
Net income 3-yr CAGR—
Margins
Gross margin20.3%
Operating margin-5,614.3%
Net margin-5,527.6%
FCF margin-3,165.7%
EBITDA margin-5,504.0%
Returns
ROE-194.5%
ROA-165.0%
ROIC (approx.)-207.8%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets26.3%
Debt / equity0.00x
Current ratio0.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-71.6%
Payout ratio—
Capex / revenue35.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $282,881 | $166,131 | $145,954 | $263,922 | $145,380 | $162,910 | $50,277 | $149,325 |
| Cost of revenue | $303,344 | $45,303 | $193,768 | $142,396 | $26,285 | $32,106 | $21,590 | $255,068 |
| Gross profit | -$20,463 | $120,828 | -$47,814 | $121,526 | $119,095 | $130,804 | $28,687 | -$105,743 |
| R&D expense | $3.57M | $4.15M | $5.93M | $5.10M | $4.48M | $4.69M | $4.87M | $4.81M |
| SG&A expense | $1.87M | $1.50M | $2.50M | $1.87M | $1.82M | $2.60M | $2.77M | $5.82M |
| Operating income | -$6.27M | -$6.20M | -$9.21M | -$26.54M | -$7.01M | -$8.06M | -$8.55M | -$11.91M |
| Pretax income | -$6.31M | -$6.26M | -$9.14M | -$26.22M | -$7.05M | -$7.72M | -$7.52M | -$11.04M |
| Income tax | $500 | $19,168 | $520 | -$473,716 | -$1.17M | $12,327 | $12,004 | -$8,175 |
| Net income | -$6.31M | -$6.28M | -$9.14M | -$25.75M | -$5.89M | -$7.73M | -$7.53M | -$11.03M |
| EBITDA | -$6.05M | -$6.00M | -$8.95M | -$26.27M | -$6.75M | -$7.77M | -$8.27M | -$11.55M |
| EPS (basic) | -1.01 | -1.46 | -4.06 | — | -4.66 | -7.00 | -7.05 | — |
| EPS (diluted) | -1.01 | -1.46 | -4.06 | — | -4.66 | -7.00 | -7.05 | — |
| Weighted avg. shares (diluted) | 6.27M | 4.31M | 2.25M | — | 1.26M | 1.10M | 1.07M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $714,803 | $3.65M | $8.23M | $11.88M | $11.44M | $11.12M | $1.90M | $2.94M |
| Short-term investments | — | — | — | — | — | $2.25M | $19.58M | $26.81M |
| Receivables | $51,828 | $52,059 | $82,339 | $190,375 | $55,905 | $210,968 | $136,391 | $132,570 |
| Inventory | $672,950 | $841,669 | $846,119 | $992,397 | $1.09M | $1.08M | $1.08M | $1.07M |
| Current assets | $1.94M | $5.19M | $9.78M | $13.69M | $14.05M | $15.31M | $23.83M | $32.29M |
| PP&E, net | $1.77M | $1.98M | $2.16M | $2.27M | $2.49M | $2.67M | $2.59M | $2.76M |
| Intangibles | $7.22M | $7.22M | $7.22M | $7.22M | $26.10M | $26.10M | $26.10M | $26.10M |
| Total assets | $12.79M | $16.59M | $21.50M | $24.74M | $44.74M | $46.47M | $55.15M | $63.56M |
| Current liabilities | $2.51M | $2.86M | $4.28M | $3.54M | $3.69M | $3.71M | $5.38M | $7.32M |
| Total liabilities | $3.37M | $3.88M | $5.46M | $4.11M | $4.91M | $5.33M | $7.23M | $9.69M |
| Shareholders' equity | $9.43M | $12.71M | $16.04M | $20.63M | $39.39M | $40.70M | $47.48M | $53.88M |
| Shares outstanding | 7.29M | 4.88M | 3.60M | 2.10M | 48.14M | 36.18M | 33.57M | 1.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.68M | -$7.15M | -$7.85M | -$6.20M | -$5.90M | -$8.29M | -$8.75M | -$8.23M |
| Capital expenditure | $15,001 | $18,281 | $142,017 | $131,969 | $75,105 | $401,060 | $91,913 | $72,987 |
| Free cash flow | -$5.70M | -$7.17M | -$7.99M | -$6.33M | -$5.98M | -$8.69M | -$8.84M | -$8.30M |
| Investing cash flow | -$15,001 | -$168,281 | -$142,017 | -$329,423 | $2.17M | $17.07M | $7.36M | $266,006 |
| Financing cash flow | $2.76M | $2.74M | $4.33M | $6.97M | $4.06M | $429,000 | $354,746 | — |
| Depreciation & amortization | $222,363 | $201,840 | $255,445 | $267,566 | $267,383 | $291,414 | $280,445 | $357,123 |
| Stock-based compensation | $255,184 | $213,752 | $219,114 | $291,975 | $500,585 | $580,265 | $875,228 | $1.32M |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.